| Identification | More | [Name]
Aucubin | [CAS]
479-98-1 | [Synonyms]
AUCUBIN
AUCUBOSIDE
B-D-GLUCOPYRANOSIDE, (1S,4AR,5S,7AS)-1,4A,5,7A-TETRAHYDRO-5-HYDROXY-7-(HYDROXYMETHYL)CYCLOPENTA[C]PYRAN-1-YL
RHINANTHIN
1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta[c]pyran-1-yl-beta-D-glucopyranoside
[1S-(1alpha,4aalpha,5alpha,7aalpha)]-1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta[c]pyran-1-yl-beta-D-glucopyranoside
AUCUBINB-D-GLUCOPYRANOSIDE, (1S,4AR,5S,7AS)-1,4A,5,7A-TETRAHYDRO-5-HYDROXY-7-(HYDROXYMETHYL)CYCLOPENTA[C]PYRAN-1-YL,
Aucubin std.
AUCUBIN(P)
AUCUBIN hplc
(2S,3R,4S,5S,6R)-2-[[(1S,4aR,5S,7aS)-5-Hydroxy-7-(hydroxymethyl)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-1-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
AUCUBIN WITH HPLC
[c]pyran-1-yl
tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta
β-D-Glucopyranoside, (1S,4aR,5S,7aS)-1,4a,5,7a-
b-D-Glucopyranoside, 1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta[c]pyran-1-yl, [1S-(1a,4a,5a,7a)]
Rhimantin
1S-(1alpha,4aalpha,5alpha,7aalpha)-1,4a,5,7a-Tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta[c]pyran-1-yl-beta-D-glucopyranoside
[(1S)-1,4aα,5,7aα-Tetrahydro-5α-hydroxy-7-(hydroxymethyl)cyclopenta[c]pyran-1α-yl]β-D-glucopyranoside
Aucubigenin 1-O-β-D-glucopyranoside | [EINECS(EC#)]
207-540-8 | [Molecular Formula]
C15H22O9 | [MDL Number]
MFCD00136026 | [Molecular Weight]
346.33 | [MOL File]
479-98-1.mol |
| Chemical Properties | Back Directory | [Melting point ]
181° | [alpha ]
D21 -163.1° (c = 1.6) | [Boiling point ]
669.0±55.0 °C(Predicted) | [density ]
1.61±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMF: 30 mg/ml; DMSO: 30 mg/ml; PBS (pH 7.2): 10 mg/ml | [form ]
neat | [pka]
12.80±0.70(Predicted) | [color ]
White | [Optical Rotation]
-16518 (H2O) | [BRN ]
50340 | [InChI]
InChI=1/C15H22O9/c16-4-6-3-8(18)7-1-2-22-14(10(6)7)24-15-13(21)12(20)11(19)9(5-17)23-15/h1-3,7-21H,4-5H2/t7-,8+,9+,10+,11+,12-,13+,14-,15-/s3 | [InChIKey]
RJWJHRPNHPHBRN-FKVJWERZSA-N | [SMILES]
[C@@]12([H])C(CO)=C[C@@H](O)[C@]1([H])C=CO[C@H]2O[C@H]1[C@H](O)[C@H]([C@H](O)[C@@H](CO)O1)O |&1:0,6,8,13,15,16,18,19,21,r| | [LogP]
-4.103 (est) | [CAS DataBase Reference]
479-98-1(CAS DataBase Reference) |
| Safety Data | Back Directory | [Risk Statements ]
R22:Harmful if swallowed. | [Safety Statements ]
S22:Do not breathe dust .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) . | [WGK Germany ]
3
| [F ]
10-23 |
| Hazard Information | Back Directory | [Chemical Properties]
Aucubin, bitter in taste, easily soluble in water, ethanol, methanol, insoluble in chloroform, ether, petroleum ether and other solvents. It is a kind of iridoid compound that widely exists in many plant species in nature. | [Uses]
Aucubine 5-Acetatea is an impurity of Aucubine (A794730). Aucubine shows antioxidant and protective effects for the liver and kidney organs, shown in mice with induced diabetes. | [Definition]
ChEBI: Aucubin is an organic molecular entity. It has a role as a metabolite. | [Mechanism of action]
Aucubin can be used to clear dampness and heat, facilitate urination, relieving pain, reduce blood pressure and protecting liver. It can promote the regeneration of stem cells, significantly inhibit the replication of hepatitis B virus DNA. | [in vivo]
Aucubin (5 mg/kg; i.p. for 15 d) has antioxidant and pancreas-protective effects on rats with streptozotocin-induced diabetes[1].
Aucubin (40-200 mg/kg; a single i.p.) exhibits significant protective activity against α-amanitin intoxication in mice[5].
Aucubin (5 mg/kg/day; i.p. for 21 d) decreases the breathing frequency, increases the lung dynamic compliance, alleviates lung parenchymal fibrotic changes, and reduces the intrapulmonary collagen disposition and inflammatory injury of BLM-stimulated mice[6].
| Animal Model: | Male Wistar rats (200-230 g) induced diabetes by a injection of streptozotocin[1] | | Dosage: | 5 mg/kg | | Administration: | I.p. twice daily for the first 5 days, followed by single injections daily for the last 10 days | | Result: | Increased the body weight of streptozotocin-diabetic rats.
Lowered the blood glucose level.
Decreased the level of lipid peroxidation and increased the activities of antioxidant enzymes.
Increased in insulin immunoreactivity and the number of immunoreactive β cells compared with untreated diabetic rats.
|
| [storage]
Store at -20°C |
|
|